Novo Nordisk shares plunge 20% after disappointing trial results; …
Dec 20, 2024 · Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point Friday after reporting trial results that missed expectations.
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
Dec 20, 2024 · The data from Novo's CagriSema Phase III trial was based on about 3,400 people with a body mass index (BMI) of 30 or above or people with a BMI of 27 and at least one weight-related comorbidity ...
Novo Nordisk A/S: CagriSema demonstrates superior weight
Dec 20, 2024 · In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with ...
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · The 68-week study showed participants on CagriSema lost about 23% of their body weight, compared with 12% for those taking cagrilintide by itself, 16% for those on semaglutide, and 2.3% for people ...
'A worst case scenario for Novo': Read the market reaction to CagriSema …
Dec 20, 2024 · Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected ...
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 10, 2024 · The Danish company is now in late-stage testing with a dual-acting experimental drug it calls cagrisema. The drug combines semaglutide, the active ingredient in Wegovy, with another compound that mimics a metabolic hormone called amylin.
Novo Nordisk A/S: CagriSema demonstrates superior weight loss …
Dec 20, 2024 · In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with ...
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles …
Dec 20, 2024 · CagriSema is a weekly injection combining semaglutide, which is the active ingredient in its blockbuster drug Wegovy and mimics the gut hormone GLP-1, with a separate molecule called cagrilintide ...
Novo’s next-gen obesity drug misses expectations in closely …
Dec 20, 2024 · The trial results announced Friday are a blow to Novo’s o besity ambitions, then, disappointing analysts and investors eager for signs it can continue to dominate a drug class projected to eventually surpass $100 billion in yearly sales. David Risinger, an analyst with Leerink Partners, wrote that, in light of the findings, “it …
Novo Nosedives on Underwhelming CagriSema Phase III Weight …
Dec 20, 2024 · Novo Nordisk on Friday released headline data from the Phase III REDEFINE 1 trial of its next-generation weight-loss therapy CagriSema, touting “superior weight loss” in people with obesity and overweight than just cagrilintide, semaglutide (marketed as Wegovy for weight loss and Ozempic for diabetes) or placebo.